Figure 1
Figure 1. Cumulative incidence of intracranial hemorrhage (ICH) in patients with metastatic brain tumors. No differences between enoxaparin and control cohorts were observed in the cumulative incidence of intracranial hemorrhage for any category (Gray test, P > .05) including measurable (A), significant (B), and total (C) hemorrhages. Enoxaparin cohort shown in red and controls in blue.

Cumulative incidence of intracranial hemorrhage (ICH) in patients with metastatic brain tumors. No differences between enoxaparin and control cohorts were observed in the cumulative incidence of intracranial hemorrhage for any category (Gray test, P > .05) including measurable (A), significant (B), and total (C) hemorrhages. Enoxaparin cohort shown in red and controls in blue.

Close Modal

or Create an Account

Close Modal
Close Modal